ASX
LCT 0.053    Last updated 4.08 am
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

The following fact sheet provides a summary of our current business and research pipeline.

Cell therapy for neurodegenerative diseases

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which restore function using naturally occurring cells.

 

LCT’s lead product, NTCELL®, is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory, producing factors to promote new central nervous system growth and repair disease-induced nerve degeneration.

 

The Phase I/IIa NTCELL clinical trial in New Zealand for the treatment of Parkinson’s disease met the primary endpoint of safety and reversed progression of the disease after one year. Results from this trial were used to design a larger Phase IIb trial to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient sub group. If the trial is successful the company will apply for provisional consent to treat paying patients in New Zealand and launch NTCELL as the first disease modifying treatment for Parkinson’s disease in 2017.

 

In addition to Parkinson’s disease, NTCELL has the potential to be used in a number of other central nervous system indications, including Huntington’s, Alzheimer’s and motor neurone diseases including amyotrophic lateral sclerosis (ALS).

 

LCT’s proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system.

 

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.

— 21 April 2016

Notice under Section 708A Corporations Act

Living Cell Technologies Limited ("the Company") has issued 8,349,010 fully paid Ordinary shares at $ 0.0517 by way of placement to eligible participants as outlined in the announcement dated 21 April 2016.

Read More Read Less

— 21 April 2016

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Read More Read Less
Load More

— 1 March 2016

LCT expects crucial Parkinson’s clinical trial results in early 2017

Australasian biotech company Living Cell Technologies says it will know the outcome of a make-or-break clinical trial on its regenerative cell therapy for Parkinson's disease in the first quarter of next year. If the trial succeeds, Living Cell's lead product NTCELL will be the world's first disease-modifying treatment for Parkinson's as existing treatments only deal with the symptoms rather than stopping the degeneration of the brain.

Read More Read Less
Load More

There are no forthcoming events at present.

Load More
Announcements

— 21 April 2016

Notice under Section 708A Corporations Act

Living Cell Technologies Limited ("the Company") has issued 8,349,010 fully paid Ordinary shares at $ 0.0517 by way of placement to eligible participants as outlined in the announcement dated 21 April 2016.

Read More Read Less

— 21 April 2016

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Read More Read Less
Load More
LCT in the News

— 1 March 2016

LCT expects crucial Parkinson’s clinical trial results in early 2017

Australasian biotech company Living Cell Technologies says it will know the outcome of a make-or-break clinical trial on its regenerative cell therapy for Parkinson's disease in the first quarter of next year. If the trial succeeds, Living Cell's lead product NTCELL will be the world's first disease-modifying treatment for Parkinson's as existing treatments only deal with the symptoms rather than stopping the degeneration of the brain.

Read More Read Less
Load More
Events

There are no forthcoming events at present.

Load More
© 2016 Living Cell Technologies Limited.
site by { brownpaperbag }